Offered a cheaper version of a prescribed medicine? In biosimilar vs generic drugs, a generic copies a chemically made brand drug, while a biosimilar is highly similar to a biologic made from living cells.
That difference decides what evidence a manufacturer must show and whether a pharmacist may swap the product without involving the prescriber. Wider coverage of drug approvals sits in medical news today.
Criteria that separate a generic from a biosimilar
Five checks settle which route a product followed and what that means at the pharmacy counter. Work through them in order, because each one narrows the next.
- Identify the molecule type. A small chemical and a protein grown in living cells are regulated differently, so this check comes first.
- Identify the evidence standard. The proof a manufacturer must supply depends on whether the product is a copy or a close match.
- Identify the application type. The application name signals the route and the paperwork behind it.
- Identify the substitution status. Whether a pharmacist can swap a product alone is a separate legal question from whether the product works.
- Identify the right database. Small-molecule and biologic products are listed in different FDA references.
Side-by-side comparison
The table applies the first four checks to both product types. Read the last column as a guide to what each difference means for expectations.
| Criterion | Generic drug | Biosimilar | Planning use |
|---|---|---|---|
| Relationship to the original | Same structure as the brand, metabolized in the same way, affecting the condition in the same way | Highly similar to an existing FDA-approved reference product, with no clinically meaningful differences | Expect a true copy from a generic and a close match from a biosimilar. |
| How it is made | Typical drugs are chemically synthesized | Very complex, made from human or animal cells, using large protein molecules | Living-cell products vary, so close matching rather than exact copying is the standard. |
| Proof required | Bioequivalence | Proof that there are no meaningful differences from the reference product | The biosimilar standard is a comparison against a specific biologic, not a bioequivalence test alone. |
| Application | Abbreviated New Drug Application (ANDA) | Biosimilar Biologics License Application (BLA) | The application name tells you which route the product took. |
The standards above come from CANDO-MS’s explainer on generics vs biosimilars and PropThink’s overview of how generic drugs are approved.
The ANDA route for generic drugs
A generic manufacturer must submit an Abbreviated New Drug Application (ANDA) to bring a copy of an approved brand drug to market, according to PropThink. The ANDA approval process is where patents come into play, and that is mostly a question of timing.
Patents and the Orange Book
All pharmaceutical patents for FDA-approved drugs are listed in the Orange Book database. Patent protection for medications lasts for 20 years, according to CANDO-MS. A generic applicant can wait for those patents to run out or challenge them.
Paragraph IV challenges
Filing an ANDA under Paragraph IV is called a Patent Challenge. If the patent holder sues within 45 days of receiving notice, a 30-month stay is granted. The first patent challenger is awarded a 180-day exclusivity period, per the PropThink summary.
These steps govern when a generic can reach the market, not how good it is. The quality standard is the sameness test covered next.
Are generics as effective as brand-name drugs?
Yes. A generic must match its brand on the points that determine effect, so patients should expect the same intended result. The Specialty Rx Toolkit notes that generics have the same active ingredients as their brand-name counterparts. It describes the FDA definition as chemically identical to the brand in dosage form, strength, method of administration and quality, as set out on its biosimilars and drug classifications page.
CANDO-MS adds the functional requirements: a generic must have the same structure, be metabolized in the same way and affect the condition in the same way. That is why bioequivalence, rather than a fresh round of full development, is the evidence a generic maker supplies.
Anyone worried about a specific switch should raise it with the prescriber or pharmacist. The sameness standard applies to the active drug, so a concern about a particular product is a question for the people who can see its label.
The biosimilar route for biologics
Biosimilars exist because biologics cannot be copied the way chemical drugs can. Biologics, or biopharmaceuticals, are drugs derived from natural sources such as bacteria or antibodies. Unlike typical drugs, which are chemically synthesized, they rely on large protein molecules, as PropThink explains. There is no such thing as a generic biologic; the equivalent product is called a biosimilar.
Legal basis and application
A manufacturer submits a biosimilar Biologics License Application showing no clinically meaningful difference from the reference product. In the FDA’s terms, as relayed by CANDO-MS, a biosimilar is highly similar to an approved reference product with no clinically meaningful differences.
Why variation is tolerated but controlled
All biologics exhibit variation, so exact sameness is not the test. CANDO-MS states that the FDA tightly controls how much a biosimilar may vary. The Specialty Rx Toolkit adds that only minor differences in clinically inactive components are allowable. Over a course of treatment, patients can expect the same safety and effectiveness from the biosimilar as from the reference product.
The practical result is a stricter comparison than a generic faces. The next question is whether a close match is also close enough for a pharmacist to hand over without a new prescription.
Interchangeable biosimilars and pharmacy substitution
An interchangeable biosimilar is a biosimilar that has met an additional standard, allowing a pharmacist to substitute it for the original product without the prescriber’s intervention. That is the interchangeable biosimilar meaning in practice, according to PropThink. The extra proof is that clinical results of the biosimilar are consistently identical to the original even when the two are used alternately.
Interchangeability builds on biosimilarity rather than replacing it. GaBI reports that, in the FDA’s 2011 position, biosimilarity must first be established before any studies to prove interchangeability. A biosimilar can therefore be approved without carrying the interchangeable label, and the label concerns who may authorize the swap.
This contrast explains the unique angle of the two routes. Generic substitution rests on sameness shown through the ANDA, while biologic substitution needs a dedicated demonstration on top of biosimilarity. Knowing which designation a product holds therefore means looking it up.
Looking up whether a product has a generic or biosimilar
Start by deciding whether the medicine is a chemically made drug or a biologic, then use the matching FDA reference. The following order works for most prescriptions.
- Ask what type of drug it is. A prescriber or pharmacist can confirm whether the product is a small-molecule drug or a biologic.
- Search the Orange Book for chemical drugs. It lists the pharmaceutical patents for FDA-approved drugs, which shows the protection a brand still carries, per PropThink.
- Search the Purple Book for biologics. The FDA’s Purple Book is the companion database for biological products, including biosimilars.
- Ask about interchangeable status. Only an interchangeable biosimilar can be substituted by the pharmacist without the prescriber’s intervention.
Choosing between the options
The choice is rarely the patient’s alone, so the aim is to know what to ask. These pointers show who each option suits.
- A generic suits chemically made brand drugs. When the brand is a small-molecule drug, the generic carries the same active ingredient and the same effect on the condition.
- A biosimilar suits biologic brands. No generic biologic exists, so the biosimilar is the lower-variation alternative within a controlled range of similarity.
- An interchangeable designation matters at the counter. It is relevant when a pharmacist may substitute without contacting the prescriber, so ask about it before a refill rather than at it.
- Headline claims need checking. News about a switch study or a pooled result should be read with how to read a medical study in mind. Where several trials are combined, systematic review vs meta-analysis explains what each design can and cannot show.
Frequently asked questions
| Question | Answer |
|---|---|
| How many biosimilars has the FDA approved? | The Specialty Rx Toolkit reports that 23 biosimilars had been approved as of December 2019, in its biosimilars overview. That figure is dated, so check the Purple Book for the current list. |
| What share of US prescriptions are generics? | Generics represented 86% of all prescriptions written in the United States in 2014, according to PropThink. |
| How long does a generic take to develop? | A generic typically takes 2-4 years to develop and move through FDA approval, compared with 10-12 years for an innovator drug, per the same PropThink overview. |
| Are generics cheaper than brand drugs? | On average, generics are 80-85% cheaper than their brand-name counterparts, according to PropThink. |
